Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Juno Therapeutics Inc. buy tamam

Start price
€32.52
25.08.15 / 50%
Target price
€51.09
18.09.15
Performance (%)
16.09%
End price
€37.75
18.09.15
Summary
This prediction ended on 18.09.15 with a price of €37.75. The prediction had a final performance of 16.09%. tamam has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Juno Therapeutics Inc. - - - -
iShares Core DAX® 1.560% 2.566% 18.261% 16.927%
iShares Nasdaq 100 0.517% 1.894% 25.521% 35.441%
iShares Nikkei 225® 1.730% 5.631% 18.569% 13.063%
iShares S&P 500 1.482% 1.594% 24.989% 38.339%

Comments by tamam for this prediction

In the thread Juno Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) 16.09%
Target price 51.089
Change
Ends at 18.09.15

collaboration agreement with oncology-giant Celgene, and an impressive pipeline

Juno Therapeutics (NASDAQ:JUNO): For my last name, I'm piggy-backing off an idea by one of the best biotech investors and smartest guys I know, Brad Loncar. Brad runs the Loncar Cancer Immunotherapy Index (LCINDX), a basket of biotech stocks that seeks to track the performance of the immuno-oncology space. Key names in the index include Celgene, Newlink Genetics, Amgen, Pfizer, Novartis, Kite, Ziopharma, and Juno Therapeutics. Brad likes Juno because they recently signed a major collaboration agreement with oncology-giant Celgene. I agree with Brad; this is a fantastic validator of the platform and should be highly lucrative for both companies. But Juno also has one heck of an impressive pipeline. If you want to play CAR or CAR T, and you should, then Juno is a must-own. The pipeline is packed with catalysts and they have over $1.3 billion in cash on hand.

Prediction Buy
Perf. (%) 16.09%
Target price 51.089
Change
Ends at 18.09.15

(Vom Mitglied beendet)